Compare LYEL & HBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYEL | HBB |
|---|---|---|
| Founded | 2018 | 1904 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.8M | 252.9M |
| IPO Year | 2021 | 2017 |
| Metric | LYEL | HBB |
|---|---|---|
| Price | $16.70 | $20.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $30.60 | N/A |
| AVG Volume (30 Days) | ★ 54.9K | 15.4K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | $36,000.00 | ★ $606,852,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8,712.13 | N/A |
| P/E Ratio | ★ N/A | $76.21 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.40 | $12.72 |
| 52 Week High | $45.00 | $21.84 |
| Indicator | LYEL | HBB |
|---|---|---|
| Relative Strength Index (RSI) | 33.73 | 54.02 |
| Support Level | $15.74 | $17.95 |
| Resistance Level | $19.02 | $20.44 |
| Average True Range (ATR) | 1.19 | 1.29 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 19.29 | 66.00 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.